July 31, 2020 - The court denied the defendants' motion to dismiss.

January 17, 2020 - A motion to dismiss the consolidated complaint was filed.

November 2019 - A consolidated complaint was filed.

December 27, 2018 - An investor in shares of Immunomedics, Inc. (NASDAQ: IMMU) filed a lawsuit in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by Immunomedics, Inc. in connection with certain allegedly false and misleading statements made between August 23, 2018 and December 20, 2018.

According to the complaint the plaintiff alleges on behalf of purchasers of Immunomedics, Inc. (NASDAQ: IMMU) common shares between August 23, 2018 and December 20, 2018, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between August 23, 2018 and December 20, 2018, the Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts.

Morris Plains, NJ based Immunomedics, Inc. a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer.
Immunomedics, Inc. reported that its Total Revenue declined from $3.09 million for the 12 months period that ended on June 30, 2017 to $2.15 million for the 12 months period that ended on June 30, 2018 and that its Net Loss increased over those time periods from $153.2 million to $273.83 million.

Shares of Immunomedics, Inc. (NASDAQ: IMMU) reached as high as $26.76 per share in August 2018.

On December 17, 2018, FDAnews.com published an article entitled “FDA Hits Immunomedics for Data Integrity Breach.” The article reported, in part, that “the FDA cited Immunomedics for a host of violations—including its handling of a data integrity breach—observed at its Morris Plains, New Jersey, drug substance manufacturing facility between August 6 and 14.”

Shares of Immunomedics, Inc. (NASDAQ: IMMU) declined to as low as $12.86 per share on December 20, 2018.